Xilio Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Xilio Therapeutics, a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, announced its participation in two investor conferences. The Cowen 43rd Annual Healthcare Conference will take place on March 6, 2023, at 9:10 a.m. ET, while the Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 13, 2023, with a virtual presentation at 4:00 p.m. ET. Investors can access live webcasts on the Xilio Therapeutics website, with replays available for 30 days post-event. The company utilizes a proprietary platform to develop therapies aimed at improving cancer treatment outcomes without systemic side effects.

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced its participation in the following upcoming investor conferences:

• Cowen 43^rd Annual Healthcare Conference on Monday, March 6, 2023, at 9:10 a.m. ET as part of a discussion called Novel Immuno-Oncology (IO) Corporate Panel.
• Oppenheimer 33^rd Annual Healthcare Conference on Monday, March 13, 2023, with a virtual presentation at 4:00 p.m. ET.

A live webcast of the presentations can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcasts will be archived on the website for 30 days following each presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated molecules, including cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting www.xiliotx.com and follow us on Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics, Inc.).

This press release contains hyperlinks to information that are not deemed to be incorporated by reference in this press release.

For Investor Inquiries:

Melissa Forst
Argot Partners
xilio@argotpartners.com

For Media Inquiries: 

Julissa Viana
Vice President, Corporate Communications
media@xiliotx.com 

FAQ

What are the upcoming investor conferences for Xilio Therapeutics?

Xilio Therapeutics will participate in the Cowen 43rd Annual Healthcare Conference on March 6, 2023, and the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023.

When will Xilio Therapeutics present at the Cowen 43rd Annual Healthcare Conference?

Xilio Therapeutics will present at the Cowen 43rd Annual Healthcare Conference on March 6, 2023, at 9:10 a.m. ET.

What is the schedule for Xilio Therapeutics at the Oppenheimer 33rd Annual Healthcare Conference?

Xilio Therapeutics will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 4:00 p.m. ET.

Where can I access the webcasts of Xilio Therapeutics' presentations?

Live webcasts of Xilio Therapeutics' presentations can be accessed under the 'Events & Presentations' section on their website.

How long will the webcasts from Xilio Therapeutics be available for replay?

The replays of the webcasts will be available for 30 days following each presentation.